Nicola Klein to Pneumococcal Infections
This is a "connection" page, showing publications Nicola Klein has written about Pneumococcal Infections.
Connection Strength
2.150
-
All Older Adults Benefit From Pneumococcal Vaccinations-The Case for Evaluating Vaccine Effectiveness Using All-Cause Pneumonia. JAMA Intern Med. 2023 01 01; 183(1):48-49.
Score: 0.836
-
Risk of underlying chronic medical conditions for invasive pneumococcal disease in adults. Vaccine. 2016 08 05; 34(36):4293-7.
Score: 0.533
-
Surveillance for invasive pneumococcal disease during 2000-2005 in a population of children who received 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2007 Sep; 26(9):771-7.
Score: 0.289
-
Safety and Tolerability of V114 Pneumococcal Vaccine in Infants: A Phase 3 Study. Pediatrics. 2023 Jul 01; 152(1).
Score: 0.216
-
Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease After Introduction Into Routine Pediatric Use. J Pediatric Infect Dis Soc. 2021 Mar 26; 10(2):141-150.
Score: 0.185
-
Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants in the United States. Pediatr Infect Dis J. 2021 10 01; 40(10):944-951.
Score: 0.048
-
A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants. Pediatr Infect Dis J. 2020 08; 39(8):763-770.
Score: 0.044